The BRAIN Foundation Synchrony 2020 Virtual Conference November 1, 8, 15, 22,
December 6, 12, 13
From Bench to BioPharma: Watch Conference Videos One mission. One platform. Everyone together.
Contact Info

Your donations to The BRAIN Foundation are tax-deductible.

Synchrony 2020 has concluded

Thank you and see you all next year!

About The Conference

The BRAIN Foundation, in partnership with UC Davis MIND Institute and CalTech, is excited to announce the second year of Synchrony.
Synchrony is the first and only international symposium on translational research in autism, that brings together academia, biotech, pharmaceutical companies and venture partners from around the world with the mission to improve health and quality of life of people with autism.
Come learn about the latest in basic and translational research and the opportunities being pursued by biotech and pharmaceutical companies for the development of FDA-approved therapeutics for autism.

Supported by




Sponsored by


Understanding ASD through animal models, tissue cultures and organoids

Treatments in the FDA pipeline undergoing clinical trials

Biotech startups and pharmaceutical companies: Novel ASD therapeutics

Meet Our Community

100+ Researcher Participants

10 BRAIN Foundation Principal Investigators Funded

$1 Million+ in Research Grants Facilitated

150+ Physicians

Day 1, November 1, 2020

Animal Models in ASD

9 AM - 2 PM PST

This session presents cutting-edge research into how mouse models are being used to help understand ASD in humans. Animal models can provide insights into effects of gene mutations, and non-behavioral features of ASD, such as the role of the immune system, metabolic system, and gastrointestinal tract including possible contributions by the gut microbiome. Knowledge from these studies may not only help inform human research, but may also prove invaluable in testing therapeutics.


Laetitia Davidovic, PhDCNRS, France
Jun Huh, PhDHarvard
Edward Quadros, PhDSUNY
Daniel Geschwind, MDUCLA
Sarkis Mazmanian, PhDCaltech
Mauro Costa-Mattioli, PhDBCM
Joseph D. Buxbaum, PhDMount Sinai
Elisa Hill-Yardin, PhDRMIT, Australia
Day 2, November 8, 2020

Organoid Research, Immunology and Neuro-metabolism

9 am - 1:15 pm, 2:15- 5:30 pm PST

The morning session highlights basic science research including organoid development and immunological research related to testing and treatment in ASD.



Paul Ashwood, PhDUC Davis
Tanja Michel, PhD/Mirolyuba Ilieva, PhDSDU/Odense University Hospital


Jonathan Kipnis, PhDWashington University School of Medicine
Andrew McKeon, MDMayo Clinic
Lisa Boulanger, PhDPrinceton
Harumi Jyonouchi, MDSt. Peters’ Hospital
Emanuela Balestrieri, PhDUniversity of Rome
Marion Leboyer, MD, PhDUniversity of Paris

The afternoon session focuses on neuro-metabolic studies in ASD, including a focus on anti-folate antibodies and treatments, mitochondrial dysfunction and chemical signaling in the nervous system.

Neuro-metabolic Studies

Randy Blakely, PhDFAU, NIMH
Vincent Ramaekers, MDUniv of Liege, Belgium
Edward Quadros, PhDSUNY
Robert Naviaux, MD, PhDUCSD
Richard Boles, MD Private Practice
Richard Frye, MD, PhDPhoenix Childrens’ Hospital
Day 3, November 15, 2020

Microbiome/GI Research

10 am - 4:30 pm PST

Several research studies link gastrointestinal comorbidities to a variety of debilitating symptoms in individuals with ASD at all ages. Improvements in GI symptoms are linked to improvements in behavior & quality of life. This session highlights the latest work in microbiome studies, therapeutics in FDA trials, updates on a longitudinal GI treatment study, & biopsy studies to characterize inflammatory conditions in individuals with ASD.



Jim Adams, PhD & Rosa Krajmalnik-Brown, PhDASU
Frederico Balzola, MDTorino Piedmont, Italy
Arthur Krigsman, MDPrivate Practice
Steve Walker, PhDWake Forest Univ.
Michael Gershon, MDColumbia University Medical Center

Microbiota Therapies

Jim Adams, PhD & Rosa Krajmalnik-Brown, PhDASU
Sabine Hazan-Steinberg, MDPrivate Practice
Sonia Michail, MDCHLA

Panel Discussion

Repurposed drugs as ASD therapeutics Dr Rossignol, MD, Dr Jyonouchi, MD, Dr Krigsman, MD, Dr Adams, PhD & Dr Yeh, MD

Day 4, November 22, 2020

Physicians Present Treatments on the Horizon in ASD

10 am - 12:15 pm, 1 - 3:30 pm PST

This session presents researchers and physicians with the latest on treatments and solutions geared towards educating physicians, parents and caregivers. Topics range from CBD studies, mitochondrial dysfunction, GI symptoms, to biophotonic devices.


Treatments on the Horizon

Antonio Hardan, MDStanford
Joanne Kurtzberg, MDDuke
Adi Aran, MDShaare Tzedek Medical Center, Israel
Yehezkel  Ben-Ari, PhDInmed, Neurichlore
Peter Lloyd-ThomasEpiphany ASD
Arthur Krigsman, MD, PhDPrivate Practice

Device Panel

Anita SaltMarche, MHScSaltmarche Health and Associates
Michael Hamblin, PhDHarvard, MGH
Margaret Naeser, PhDBoston University
Paolo Cassano, MD, PhDHarvard, Mass General
Day 5, December 6, 2020

Clinical Trials for Therapeutics in ASD

9 am - 12 pm, 1 - 5 pm PST

This session brings together industry and academia with a focus on clinical trials.


Academic Sessions

The morning session highlights assessments in ASD clinical trials in the time of COVID

Bob Hendren, DOUCSF
Pam Ventola, PhDYale
Sophy Kim, PhDCornell
Whitney Ence, PhDUCSF
Ann Neumeyer, PhDMGH, Harvard
Lisa Nowinski, PhDMGH, Harvard

Industry Presentations

Industry experts from startups and large pharma will discuss ongoing clinical trials and therapeutics on the path to FDA approval.

Manuela IngallinesiServier
Stewart Campbell, PhDAxial Therapeutics
Gahan Pandina, PhDJohnson and Johnson
Joan Fallon, MScCuremark
Kevin Sanders, MDRoche
Jim Adams, PhD & Rosa Krajmalnik-Brown, PhDASU
Day 6, December 12, 2020

Novel therapeutics

10 am - 12 pm, 1 - 3 pm PST

This session highlights novel therapeutics from leaders in academia and industry. Leading companies present products in the pipeline for ASD.


Sean O’SullivanO’Sullivan Foundation
Robert Naviaux, MD, PhDUCSD
Joseph Palumbo, MDZynerba Pharmaceuticals
Stuart Lipton, MD, PhDScripps/UCSD
Paul Song, MDNK Max America
John Rodakis, MBAN of One
Mark Smith, PhDFinch Therapeutics
Nebojsa Janjic, PhDCrestone Pharma
Lynn DurhamStalicla
Kevin Shapiro, MD, PhDCortica
Day 7, December 13, 2020

Biomarker Research

10 am - 12 pm, 1 - 3 pm PST

This session brings together academic and industry efforts at establishing biomarkers to help diagnose sub-types of medical comorbidities in autism and to measure response to therapeutics and clinical trials.


The biomarker track presents leaders and innovators involved in discovering biomarkers to help identify and track conditions in people with ASD.

John SlatteryBio Rosa
Jamie McPartland, PhD Yale School of Medicine

Julian Tillman, PhD Roche

Alessio Fasano, MDMass General
Matt Anderson, MD, PhDHarvard
Judy Van de Water, PhDUC Davis
Chris Chatham, PhDRoche
Diane Stephenson, PhDC-Path Institute
Juergen Hahn, PhDRensselaer Polytechnic Institute

Panel Discussion

Clinical Validation and Biomarkers- what do they do for diagnostics and treatment tracking with Richard Frye, MD, PhD


  • The venue, people and events were top-notch. If they do it again, I would highly encourage those interested in learning first-hand about emerging autism research and clinical trials to attend this valuable event.

    John Rodakis
    Founder, N of One
  • Synchrony 2019 facilitated collaboration between researchers, clinicians and parent advocates on complex autism related issues that can only be fully answered through multidisciplinary collaboration.

    A leading UK Autism Charity
Synchrony 2020 Full Access Pass Benefits

Researcher Members

Have access to:
  • Presentation recordings of all Synchrony 2020 sessions and corresponding slides
  • Private breakout rooms during Synchrony on specific topics with speakers and your peers
  • Related talks and presentations hosted by BRAIN through the next 12 months 
  • Speakers in Q&A session through Whova platform
  • Included annual membership to Brain Foundation as a Researcher Member
  • Priority access to future speaking/poster presentation invitations and RFPs for research grants
  • Membership in an elite group of researchers/mentors from esteemed institutions. 
  • Patient group interested in studies and clinical trials
  • Industry partners catering to research supplies
  • Our newsletter with information on latest publications and announcements from the BRAIN Foundation.

Clinicians/Other Professionals:

Have Accesss to:
  • Presentation recordings of all Synchrony 2020 sessions and corresponding slides
  • Private breakout rooms during Synchrony on specific topics with speakers and your peers
  • CME opportunities announced to our physician/provider members
  • Related talks and presentations hosted by BRAIN through the next 12 months 
  • Speakers in Q&A session through Whova platform
  • Patients in a registry for supported treatment studies
  • Included annual membership to Brain Foundation as a Physician Member. 

Autism Community/Parents/Caregivers

Have Access to:
  • Presentation recordings of all Synchrony 2020 sessions and slides
  • Opportunity to have questions answered by speakers on a priority basis
  • Annual membership for BRAIN Foundation that offers:
    • Free access to additional webinars, presentations and Q&A by scientists, clinicians, industry leaders organized by BRAIN over the next 12 months
    • Notification about upcoming BRAIN funded clinical trials and opportunity to enroll as participants
    • Access to registry and health passport to enable participation in clinical trials and treatment studies
    • Discounts on services related to medical care (e.g., tests kits)
    • Information about cutting-edge science, resources and therapeutics through our newsletter (opt-out available